Abdelhalim Nermeen Mohamed, Samhan Ahmed Fathy
Department of Physical Therapy, New Kasr El-Aini Teaching Hospital, Faculty of Medicine, Cairo University, Egypt.
Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Saudi Arabia.
Turk J Phys Med Rehabil. 2022 Jun 1;68(2):246-253. doi: 10.5606/tftrd.2022.8065. eCollection 2022 Jun.
This study was aimed to evaluating the influences of methotrexate iontophoresis on functional lifestyle disabilities, functional capacity, and pain after a 6-min walking distance (6MWD) test in patients with plantar psoriasis (PP).
Forty‑five patients (29 females, 16 males; mean age 33.9±6.6 years; range, 20 to 45 years) with hyperkeratotic PP were enrolled in the randomized, placebo-controlled, parallel-groups, double-blinded study. They were assigned randomly into the active methotrexate iontophoresis (MI) group (n=23) and the placebo iontophoresis group (n=22). The patients in both groups were assessed before starting the treatment intervention and after completing eight sessions of the treatment intervention through functional lifestyle disabilities measured on the Arabic version of psoriasis disability index, functional capacity using the 6MWD test, and pain after the 6MWD test.
The pre-treatment measurements of the three variables among the two groups did not reveal statistically significant differences (p>0.05). However, there were statistically significant differences in the post-treatment results between the two groups (p<0.05). Additionally, the pre-and post-treatment values of the three outcome measures revealed statistically significant differences within the MI group (p<0.05). In contrast, there were no significant differences within the placebo group (p>0.05).
Methotrexate iontophoresis is effective in improving functional lifestyle disabilities, enhancing functional capacity, and decreasing pain in patients with PP.
本研究旨在评估甲氨蝶呤离子导入对足底银屑病（PP）患者在6分钟步行距离（6MWD）测试后的功能性生活障碍、功能能力和疼痛的影响。
45例（29例女性，16例男性；平均年龄33.9±6.6岁；范围20至45岁）患有角化过度型PP的患者被纳入随机、安慰剂对照、平行组、双盲研究。他们被随机分为活性甲氨蝶呤离子导入（MI）组（n = 23）和安慰剂离子导入组（n = 22）。两组患者在开始治疗干预前以及完成八次治疗干预后，通过使用阿拉伯语版银屑病残疾指数测量功能性生活障碍、使用6MWD测试评估功能能力以及在6MWD测试后评估疼痛情况进行评估。
两组间这三个变量的治疗前测量结果未显示出统计学显著差异（p>0.05）。然而，两组间治疗后的结果存在统计学显著差异（p<0.05）。此外，MI组内这三个结局指标的治疗前后值显示出统计学显著差异（p<0.05）。相比之下，安慰剂组内无显著差异（p>0.05）。
甲氨蝶呤离子导入对改善PP患者的功能性生活障碍、增强功能能力以及减轻疼痛有效。
